Baillie Gifford & Co. Has $4.97 Million Stock Holdings in Medpace Holdings, Inc. (NASDAQ:MEDP)

Baillie Gifford & Co. lifted its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 175.6% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 14,876 shares of the company's stock after purchasing an additional 9,478 shares during the period. Baillie Gifford & Co.'s holdings in Medpace were worth $4,966,000 as of its most recent filing with the SEC.

Other hedge funds have also bought and sold shares of the company. Swiss National Bank increased its stake in Medpace by 0.4% during the first quarter. Swiss National Bank now owns 48,400 shares of the company's stock valued at $19,561,000 after purchasing an additional 200 shares during the last quarter. ProShare Advisors LLC boosted its stake in Medpace by 3.1% in the first quarter. ProShare Advisors LLC now owns 3,337 shares of the company's stock valued at $1,349,000 after acquiring an additional 101 shares during the period. Picton Mahoney Asset Management bought a new position in shares of Medpace during the first quarter valued at approximately $2,926,000. Blair William & Co. IL lifted its holdings in shares of Medpace by 43.4% in the 1st quarter. Blair William & Co. IL now owns 24,851 shares of the company's stock worth $10,044,000 after purchasing an additional 7,521 shares during the last quarter. Finally, J.Safra Asset Management Corp boosted its holdings in shares of Medpace by 87.0% during the first quarter. J.Safra Asset Management Corp now owns 101 shares of the company's stock valued at $41,000 after acquiring an additional 47 shares during the period. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. Jefferies Financial Group downgraded Medpace from a "buy" rating to a "hold" rating and reduced their price objective for the stock from $415.00 to $345.00 in a research report on Wednesday, September 25th. Baird R W lowered shares of Medpace from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, October 23rd. Robert W. Baird lowered Medpace from an "outperform" rating to a "neutral" rating and cut their price objective for the company from $413.00 to $349.00 in a report on Wednesday, October 23rd. Redburn Atlantic initiated coverage on Medpace in a report on Monday, October 14th. They set a "buy" rating and a $404.00 target price for the company. Finally, Deutsche Bank Aktiengesellschaft lowered their price objective on shares of Medpace from $395.00 to $336.00 and set a "hold" rating on the stock in a research report on Wednesday, July 24th. Seven research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $380.00.

Medpace Trading Down 5.2 %

Medpace stock traded down $18.97 during trading hours on Thursday, reaching $342.97. 121,968 shares of the company were exchanged, compared to its average volume of 276,864. Medpace Holdings, Inc. has a 12 month low of $268.80 and a 12 month high of $459.77. The stock has a 50-day moving average of $342.27 and a 200 day moving average of $376.61. The firm has a market cap of $10.66 billion, a price-to-earnings ratio of 31.08, a PEG ratio of 2.00 and a beta of 1.37.

Medpace (NASDAQ:MEDP - Get Free Report) last released its earnings results on Monday, October 21st. The company reported $3.01 EPS for the quarter, beating the consensus estimate of $2.77 by $0.24. Medpace had a net margin of 17.66% and a return on equity of 50.87%. The firm had revenue of $533.32 million during the quarter, compared to analysts' expectations of $540.99 million. The business's quarterly revenue was up 8.3% compared to the same quarter last year. During the same period in the prior year, the company earned $2.22 EPS. As a group, research analysts forecast that Medpace Holdings, Inc. will post 11.93 EPS for the current year.

About Medpace

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.